Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection
Status:
Recruiting
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
The trial will evaluate the safety and efficacy of letermovir antiviral treatment of active
cytomegalovirus infection or cytomegalovirus disease in patients with infections that are
refractory or resistant to available treatments or who are experiencing organ dysfunction
that makes unsafe the use of available antiviral treatments.